JP3650697B2 - P-related gene expression inhibitor and cosmetics containing the same - Google Patents
P-related gene expression inhibitor and cosmetics containing the same Download PDFInfo
- Publication number
- JP3650697B2 JP3650697B2 JP08937698A JP8937698A JP3650697B2 JP 3650697 B2 JP3650697 B2 JP 3650697B2 JP 08937698 A JP08937698 A JP 08937698A JP 8937698 A JP8937698 A JP 8937698A JP 3650697 B2 JP3650697 B2 JP 3650697B2
- Authority
- JP
- Japan
- Prior art keywords
- gene expression
- related gene
- expression inhibitor
- weight
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Description
【0001】
【発明の属する技術範囲】
本発明は、P関連遺伝子に起因する、老人性シミ等の色素異常の改善・予防に好適な、P関連遺伝子発現抑制剤及びそれを含有する化粧料に関する。
【0002】
【従来の技術】
色白の美しい肌は、古来より全人が希望してきたことであり、この様な肌を得るために数々の努力が為されてきた。この中で、色の白さ、言い換えれば色の黒さの原因が、メラノサイトで生成されるメラニンであることが明らかにされた。このメラニンの量の多少により、肌の色が黒くなったり白くなったりすることも解明された。このメラニンの生合成には、チロシナーゼやチロシナーゼ関連蛋白質群と呼ばれる蛋白が関与していることも既に知られていることである。又、この様な酵素等の働きを阻害し色白を具現化するための素材や化粧料が開発され、かなりの程度は色を白くすることが可能になってきた。しかしながら、色黒とメラニンの生合成の関係についてこれらからでは説明しきれない因子が残っており、又、色黒について、その種類によってメラニンの生合成の関係因子が異なっていることもおぼろげながら知られるようになってきた。更に、上記のメカニズムによるメラニン生成阻害剤やそれを含有する化粧料では対処できない色黒も存在することは確かである。この様な色黒として、老人性シミ等が例示できる。
【0003】
一方、本発明で言うP関連遺伝子とは、マウスにおいて第7遺伝子上に発見されたピンクアイド・ダイリューション(Pink-eyed dilution)遺伝子、人に於けるP遺伝子などマウスのピンクアイド・ダイリューション(Pink-eyed dilution)遺伝子と極めて相同性の高い、各種動物の遺伝子の総称を意味する。これらのP関連遺伝子はメラニン生成にかかわっていることが知られている。この内、ピンクアイド・ダイリューション(Pink-eyed dilution)遺伝子とP遺伝子については、その塩基配列も多くの部分が明らかになっている。更にこの遺伝子を組み込んだベクターも既に知られている。しかし具体的な色素異常の種類とこの遺伝子の因果関係について論じた報告は極めて少ない。更に、P関連遺伝子を抑制する物質については、知られている情報は更に少ない。
【0004】
一方、クジンのエッセンスについて、これを含有する化粧料が美白作用を有することは既に知られていることであるが、このものがP関連遺伝子の発現を抑制すること及びP関連遺伝子の発現に起因する老人性シミ等のメラニン生成異常の改善・予防に好適であることは全く知られていなかった。
【0005】
【発明が解決しようとする課題】
本発明は老人性シミ等の従来の技術で克服が難しかったメラニン生成異常のメカニズムを明らかにし、この様な色素異常症の予防・改善に好適な手段を提供することを課題とする。
【0006】
【課題の解決手段】
この様な状況を踏まえて、本発明者らは鋭意研究努力を重ねた結果、老人性のシミに於いて、P関連遺伝子の発現昂進が見られることを見いだした。更に検討を重ねた結果、P関連遺伝子の発現をクジンのエッセンスが抑制することを見いだした。更に、このクジンのエッセンスがP関連遺伝子の発現を抑制することにより、老人性のシミを改善することを見いだし、発明を完成させるに至った。以下、本発明について発明の実施の形態を中心に更に詳細に説明を加える。
【0007】
【発明の実施の形態】
(1)本発明のP関連遺伝子発現抑制剤
本発明のP関連遺伝子発現抑制剤は、クジンのエッセンスからなる。本発明で言うエッセンスとは、植物体それ自身、植物体を乾燥・細切・粉砕などした加工物、植物体の一部又は全部或いは加工物に溶媒を加え、抽出した抽出物とその溶媒除去物、抽出物やその溶媒除去物をカラムクロマトグラフィーや液液抽出等で精製した精製物等が例示できる。この中で特に好ましいものは抽出物、抽出物の溶媒除去物、精製物である。この場合、溶媒抽出は、水、メタノールや1,3−ブタンジオール等のアルコール、アセトンやメチルエチルケトン等のケトン類、酢酸エチルや蟻酸メチル等のエステル類、クロロホルムや塩化メチレン等のハロゲン化炭化水素類、アセトニトリル等のニトリル類、ジエチルエーテルやテトラヒドロフラン等のエーテル類から選ばれる1種乃至は2種以上を植物体或いはその加工物に対して1〜20倍量を加え、室温であれば数日間、沸点付近の温度であれば数時間浸漬すればよい。浸漬後は、濾過などにより不溶物を取り除き、必要に応じて減圧濃縮や凍結乾燥をして溶媒を除去すればよい。かかる抽出の好ましい溶媒は、極性溶媒であり、特にアルコール類を含むものが好ましい。これは、有効成分がこの様な溶媒に抽出されやすいからである。又、植物体の使用部位としては特段の限定は受けないが、地下部が特に好ましい。これはこれらの部分にP関連遺伝子の発現を抑制する物質が特に多く含まれているからである。かくして得られたクジンのエッセンスは、P関連遺伝子の発現の抑制効果に優れるため、P関連遺伝子発現抑制剤としてP関連遺伝子に起因するメラニン生成の異常の改善・予防に大変有用である。
【0008】
(2)本発明の化粧料
本発明の化粧料は、上記P関連遺伝子発現抑制剤を含有し、P関連遺伝子に起因するメラニン生成異常の改善・予防に好適であることを特徴とする。本発明の化粧料に於ける、P関連遺伝子発現抑制剤の好ましい含有量は、0.01〜10重量%であり、更に好ましくは、0.05〜5重量%である。これは少なすぎると、効果が期待できない場合があり、多すぎても効果が頭打ちになるからである。本発明の化粧料に於いて、上記P関連遺伝子発現抑制剤以外に、通常化粧料で通常使用される任意成分を含有することができる。かかる任意成分としては、例えば、ワセリンやマイクロクリスタリンワックス等のような炭化水素類、ホホバ油やゲイロウ等のエステル類、牛脂、オリーブ油等のトリグリセライド類、セタノール、オレイルアルコール等の高級アルコール類、ステアリン酸、オレイン酸等の脂肪酸、グリセリンや1,3−ブタンジオール等の多価アルコール類、非イオン界面活性剤、アニオン界面活性剤、カチオン界面活性剤、両性界面活性剤、エタノール、カーボポール等の増粘剤、防腐剤、紫外線吸収剤、抗酸化剤、色素、粉体類、ビタミンCとその誘導体やアルブチン等の美白物質、メラニン産生阻害剤等が例示できる。これらの任意成分の内、特に好ましいものは、従来から知られている、ビタミンCとその誘導体やアルブチン等の美白物質やメラニン産生阻害剤である。これは、本発明のP関連遺伝子発現抑制剤とともにこの様な物質を使用することにより相乗効果を得ることができるからである。本発明の化粧料は、例えば、老人性シミのように、P関連遺伝子が関連するメラニン産生異常に対して、P関連遺伝子の発現を抑制し、メラニン産生を抑え、かかるメラニン産生異常を改善し、或いは症状が更に悪化するのを予防する作用を有する。本発明の化粧料の適用方法は、従来の美白化粧料に準じて適用することができ、例えば、0.1〜0.5gを一日数回塗布すればよい。
【0009】
【実施例】
以下に実施例を挙げて更に詳細に本発明について説明を加えるが、本発明がかかる実施例にのみ限定を受けないことは言うまでもない。
【0010】
<実施例1>
クジンの地下部を1kg集め、これに10lのメタノールを加え、5日間室温で浸漬しておき、濾過により不溶物を除去し、減圧乾固し、塩化メチレンと水で液液抽出を行い塩化メチレン層を取り、減圧乾固し、本発明のP関連遺伝子発現抑制剤1を41g得た。
【0011】
<実施例2>
プラスチック培養フラスコ(25cm2)に10%FBS加イーグルの最少培地に9×104個のマウスメラノーマB−16細胞を播種し5%炭酸ガス加、37℃の条件で24時間培養し、P関連遺伝子発現抑制剤1をDMSOにとかし、終濃度1×10-3(W/V)%になるように加え更に2日間培養した。この時、DMSOの濃度は0.2%を越えないように留意した。対照例はDMSOとした。培養終了後、燐酸緩衝生理食塩水で洗浄した後、トリプシン処理をして細胞を剥離させ、遠心分離で集め、燐酸緩衝生理食塩水で洗浄し、TRI−REAGENTを加え細胞を溶解した。この細胞溶解液1mlあたり100μlのクロロホルムを加え、遠心分離し、水層を取り500μlのイソプロパノールを加え、攪拌し、遠心分離してRNAを沈殿させた。上澄みを捨て、75%のエタノールでペレットを洗浄し、300μlのフォルマゾール(FORMAZOL、モレキュラー・リサーチ・センター製)にペレットを溶かし、分光光度によりRNAの濃度を測定し、調整した。この液を用いてノーザンブロッティングを行い、P関連遺伝子を検出した。この時、プローブとしては、ピンクアイド・ダイリューション遺伝子を用いた。即ち、この溶解液を用い、1レーンあたり8μgのRNAをホルムアルデヒド法にて、アガロースゲル電気泳動を行いキャピラリー法によりナイロンメンブランに転写した。紫外線照射によりRNAをメンブランに固定した後、ホルムアミド50%を含有するプレハイブリダイゼーション液(シグマ社製)にて数時間42℃にてプレハイブリダイゼーションを行った。プレハイブリダイゼーション液を交換した後、ランダムプライマー法にてラベルしたプローブを加え、1晩42℃でハイブリダイゼーションを行い、2×SSPE0.1%SDS、42℃で一回洗浄した後、メンブランに残った放射活性を測定しながら、SSPEの濃度を下げ、放射活性が適当なところで洗浄をやめ、X線フィルムを用いてオートラジオグラフィーによりバンドを検出した。このノーザンブロッティングの結果を図1に示す。この図より、本発明のP関連遺伝子発現抑制剤1は、対照に比し著しくP関連遺伝子の発現を抑制していることがわかる。
【0012】
<実施例3>
以下に示す処方に従って、本発明の化粧料を作製した。即ち、処方成分を室温で攪拌溶解し、本発明の化粧料である化粧水を得た。
P関連遺伝子発現抑制剤1 1 重量部
ポリオキシエチレン(60)硬化ヒマシ油 0.5重量部
エタノール 10 重量部
グリセリン 5 重量部
水 83.5重量部
【0013】
<実施例4>
以下に示す処方に従って、本発明の化粧料を作製した。即ち、処方成分を室温で攪拌溶解し、本発明の化粧料である化粧水を得た。
P関連遺伝子発現抑制剤1 0.1重量部
ポリオキシエチレン(60)硬化ヒマシ油 0.5重量部
エタノール 10 重量部
グリセリン 5 重量部
水 84.4重量部
【0014】
<実施例5>
以下に示す処方に従って、本発明のクリームを作製した。即ち、イの成分を良く混練りした後、80℃に加熱し、ロ、ハを予め80℃に予熱しておき、イにロを加え希釈し、これにハを徐々に加え乳化し、攪拌冷却しクリームを得た。
イ
トリグリセリンジイソステアレート 5 重量部
マルチトール70%水溶液 5 重量部
グリセリン 3 重量部
1,3−ブタンジオール 5 重量部
P関連遺伝子発現抑制剤1 0.7重量部
メチルパラベン 0.2重量部
ブチルパラベン 0.1重量部
ロ
流動パラフィン 15 重量部
マイクロクリスタリンワックス 3 重量部
ネオペンチルグリコールジイソオクタネート 5 重量部
カルナウバワックス 2 重量部
ハ
水 56 重量部
【0015】
<実施例6>
上記実施例3〜5の化粧料を用いて、老人性シミに悩む人を対象に使用テストを行った。即ち、老人性シミに悩む人63名を1群7人、全9群に分け、実施例3〜5の化粧料、実施例3〜5の化粧料のP関連遺伝子発現抑制剤1をアルブチンに置き換えた比較例1〜3の化粧料、実施例3〜5の化粧料のP関連遺伝子発現抑制剤1を水に置き換えた対照例1〜3の化粧料をそれぞれ2カ月使用してもらい、老人性シミの改善度を++:殆ど消失、+:明らかに減少、±:やや減少、−:不変の基準で判定してもらった。結果を表1に示す。これより、本発明のP関連遺伝子発現抑制剤を含有する化粧料は、P関連遺伝子の発現を抑制するが故に老人性シミを改善する作用に優れることがわかる。
【0016】
【表1】
【0017】
【発明の効果】
本発明によれば、老人性シミ等の従来の技術で克服が難しかったメラニン生成異常のメカニズムを明らかにし、この様な色素異常症の予防・改善に好適な手段を提供することができる。
【図面の簡単な説明】
【図1】 本発明のP関連遺伝子発現抑制剤1のノーザンブロットを示す図である。[0001]
[Technical scope to which the invention belongs]
The present invention relates to a P-related gene expression inhibitor suitable for the improvement / prevention of pigment abnormalities such as senile stains caused by P-related genes, and a cosmetic containing the same.
[0002]
[Prior art]
Fair-skinned beautiful skin has been desired by all since ancient times, and many efforts have been made to obtain such skin. In this, it was clarified that the cause of the whiteness of color, in other words, the blackness of color, is melanin produced in melanocytes. It has also been clarified that the skin color becomes black or white depending on the amount of melanin. It is already known that proteins called tyrosinase and tyrosinase-related proteins are involved in the biosynthesis of melanin. In addition, materials and cosmetics have been developed to inhibit the action of such enzymes and the like to realize fairness, and it has become possible to whiten the color to a considerable extent. However, there are still unexplained factors regarding the relationship between the color black and melanin biosynthesis, and the factors related to the biosynthesis of melanin differ depending on the type of color black. It has become known. Furthermore, there are certainly colored blacks that cannot be dealt with by melanin inhibitors by the above-mentioned mechanism and cosmetics containing them. Examples of such dark black include senile stains.
[0003]
On the other hand, the P-related gene referred to in the present invention means a pink-eyed dilution gene found on the seventh gene in mice, a P-gene in humans, and the like. This is a general term for genes of various animals that have extremely high homology with the pink-eyed dilution gene. These P-related genes are known to be involved in melanin production. Of these, the pink-eyed dilution gene and the P gene have been revealed in many parts. Furthermore, vectors incorporating this gene are already known. However, there are very few reports that discuss the specific types of pigment abnormalities and the causal relationship of this gene. Furthermore, there is much less known information about substances that suppress P-related genes.
[0004]
On the other hand, regarding the essence of kujin, it is already known that cosmetics containing it have a whitening action, but this is due to the suppression of the expression of P-related genes and the expression of P-related genes. It has not been known at all that it is suitable for the improvement and prevention of abnormal melanin production such as senile stains.
[0005]
[Problems to be solved by the invention]
It is an object of the present invention to clarify the mechanism of melanogenesis abnormality that has been difficult to overcome by conventional techniques such as senile stains, and to provide means suitable for the prevention and improvement of such dyschromia.
[0006]
[Means for solving problems]
Based on this situation, the present inventors made extensive research efforts and found that expression of P-related genes was promoted in senile spots. As a result of further studies, it was found that the expression of P-related genes was suppressed by the essence of kujin. Furthermore, the present inventors have found that this essence of kujin improves senile stains by suppressing the expression of P-related genes, and has completed the invention. Hereinafter, the present invention will be described in more detail with a focus on embodiments of the invention.
[0007]
DETAILED DESCRIPTION OF THE INVENTION
(1) P-related gene expression inhibitor of the present invention The P-related gene expression inhibitor of the present invention comprises the essence of kujin. The essence referred to in the present invention is the plant itself, a processed product obtained by drying, chopping, and pulverizing the plant, adding a solvent to a part or all of the plant, or the processed product, and extracting the extract and removing the solvent. And purified products obtained by purifying a product, an extract and a solvent-removed product thereof by column chromatography, liquid-liquid extraction, or the like. Among these, an extract, a solvent removed product of the extract, and a purified product are particularly preferable. In this case, the solvent extraction is performed using water, alcohols such as methanol and 1,3-butanediol, ketones such as acetone and methyl ethyl ketone, esters such as ethyl acetate and methyl formate, and halogenated hydrocarbons such as chloroform and methylene chloride. 1 to 2 or more kinds selected from nitriles such as acetonitrile and ethers such as diethyl ether and tetrahydrofuran are added to the plant body or processed product thereof at room temperature for several days. What is necessary is just to immerse for several hours if it is the temperature of the boiling point vicinity. After soaking, removing the more insolubles such as filtration, solvent may be removed by vacuum concentration or freeze-dried as necessary. A preferable solvent for such extraction is a polar solvent, and a solvent containing alcohols is particularly preferable. This is because the active ingredient is easily extracted into such a solvent. In addition, the use part of the plant body is not particularly limited, but the underground part is particularly preferable. This is because these parts contain a particularly large amount of substances that suppress the expression of P-related genes. The essence of kujin thus obtained is excellent in the effect of suppressing the expression of P-related genes, and is therefore very useful as a P-related gene expression inhibitor for improving / preventing abnormal melanin production caused by P-related genes.
[0008]
(2) Cosmetics of the present invention The cosmetics of the present invention contain the aforementioned P-related gene expression inhibitor and are suitable for the improvement / prevention of melanin production abnormalities caused by P-related genes. The preferable content of the P-related gene expression inhibitor in the cosmetic of the present invention is 0.01 to 10% by weight, and more preferably 0.05 to 5% by weight. This is because if the amount is too small, the effect may not be expected, and if the amount is too large, the effect reaches its peak. In the cosmetic of the present invention, in addition to the P-related gene expression inhibitor, an optional ingredient usually used in cosmetics can be contained. Examples of such optional components include hydrocarbons such as petrolatum and microcrystalline wax, esters such as jojoba oil and gallow, triglycerides such as beef tallow and olive oil, higher alcohols such as cetanol and oleyl alcohol, and stearic acid. Fatty acids such as oleic acid, polyhydric alcohols such as glycerin and 1,3-butanediol, nonionic surfactants, anionic surfactants, cationic surfactants, amphoteric surfactants, ethanol, carbopol, etc. Examples thereof include sticky agents, preservatives, ultraviolet absorbers, antioxidants, pigments, powders, whitening substances such as vitamin C and its derivatives and arbutin, and melanin production inhibitors . Among these optional components, particularly preferred are vitamin C and its derivatives, whitening substances such as arbutin, and melanin production inhibitors, which are conventionally known. This is because a synergistic effect can be obtained by using such a substance together with the P-related gene expression inhibitor of the present invention. The cosmetic of the present invention suppresses the expression of P-related genes, suppresses melanin production, and improves such melanin production abnormalities, for example, for melanin production abnormalities related to P-related genes like senile stains. Or, it has the effect of preventing further deterioration of symptoms. The application method of the cosmetic of the present invention can be applied according to conventional whitening cosmetics, and for example, 0.1 to 0.5 g may be applied several times a day.
[0009]
【Example】
Hereinafter, the present invention will be described in more detail with reference to examples, but it is needless to say that the present invention is not limited to such examples.
[0010]
<Example 1>
Collect 1 kg of Kujin underground, add 10 l of methanol, soak for 5 days at room temperature, remove insoluble matter by filtration, dry under reduced pressure, liquid-liquid extraction with methylene chloride and water, methylene chloride The layer was taken and dried under reduced pressure to obtain 41 g of the P-related gene expression inhibitor 1 of the present invention.
[0011]
<Example 2>
9 × 10 4 mouse melanoma B-16 cells were seeded in a minimal culture medium of 10% FBS-added eagle in a plastic culture flask (25 cm 2 ), cultured at 37 ° C. for 24 hours with 5% carbon dioxide, P-related The gene expression inhibitor 1 was dissolved in DMSO, added to a final concentration of 1 × 10 −3 (W / V)%, and further cultured for 2 days. At this time, attention was paid so that the concentration of DMSO would not exceed 0.2%. The control example was DMSO. After completion of the culture, the cells were washed with phosphate buffered saline and then treated with trypsin to separate the cells, collected by centrifugation, washed with phosphate buffered saline, and TRI-REAGENT was added to lyse the cells. 100 μl of chloroform was added per 1 ml of the cell lysate, centrifuged, the aqueous layer was removed, 500 μl of isopropanol was added, stirred, and centrifuged to precipitate RNA. The supernatant was discarded, the pellet was washed with 75% ethanol, the pellet was dissolved in 300 μl of formazole (FORMAZOL, manufactured by Molecular Research Center), and the RNA concentration was measured and adjusted by spectrophotometry. Northern blotting was performed using this solution to detect P-related genes. At this time, a pink eye dilution gene was used as a probe. That is, using this lysate, 8 μg of RNA per lane was subjected to agarose gel electrophoresis by the formaldehyde method and transferred to a nylon membrane by the capillary method. After immobilizing RNA on the membrane by ultraviolet irradiation, prehybridization was performed at 42 ° C. for several hours with a prehybridization solution containing 50% formamide (manufactured by Sigma). After exchanging the prehybridization solution, add a probe labeled by the random primer method, perform hybridization overnight at 42 ° C, wash once with 2 x SSPE 0.1% SDS at 42 ° C, and then remain on the membrane. While measuring the radioactivity, the concentration of SSPE was lowered, washing was stopped where the radioactivity was appropriate, and the band was detected by autoradiography using an X-ray film. The result of this northern blotting is shown in FIG. From this figure, it can be seen that the P-related gene expression inhibitor 1 of the present invention remarkably suppresses the expression of the P-related gene compared to the control.
[0012]
<Example 3>
In accordance with the formulation shown below, the cosmetic composition of the present invention has been created made. That is, the prescription ingredients were stirred and dissolved at room temperature to obtain a lotion that is the cosmetic of the present invention.
P-related gene expression inhibitor 1 1 part by weight polyoxyethylene (60) hydrogenated castor oil 0.5 part by weight ethanol 10 parts by weight glycerin 5 parts by weight water 83.5 parts by weight
<Example 4>
In accordance with the formulation shown below, the cosmetic composition of the present invention has been created made. That is, the prescription ingredients were stirred and dissolved at room temperature to obtain a lotion that is the cosmetic of the present invention.
P-related gene expression inhibitor 1 0.1 part by weight polyoxyethylene (60) hydrogenated castor oil 0.5 part by weight ethanol 10 parts by weight glycerin 5 parts by weight water 84.4 parts by weight
<Example 5>
In accordance with the formulation shown below, the cream of the present invention has been created made. That is, after knead | mixing the component of (a) well, it heats to 80 degreeC, pre-heats (b) and (c) beforehand to 80 degreeC, dilutes by adding (b) to (b), and emulsifies, stirs and adds it gradually. Cooled to obtain a cream.
Itoliglycerin diisostearate 5 parts by weight Maltitol 70% aqueous solution 5 parts by weight Glycerin 3 parts by weight 1,3-butanediol 5 parts by weight P-related gene expression inhibitor 1 0.7 part by weight methylparaben 0.2 part by weight butylparaben 0.1 parts by weight liquid paraffin 15 parts by weight microcrystalline wax 3 parts by weight neopentyl glycol diisooctanoate 5 parts by weight carnauba wax 2 parts by weight water 56 parts by weight
<Example 6>
Using the cosmetics of Examples 3 to 5 above, a use test was performed on a person suffering from senile stains. That is, 63 people who suffer from senile stains are divided into 7 groups, 9 groups in all, and the P-related gene expression inhibitor 1 of Examples 3 to 5 and the cosmetics of Examples 3 to 5 are changed to arbutin The cosmetics of Comparative Examples 1 to 3 replaced, and the cosmetics of Comparative Examples 1 to 3 in which the P-related gene expression inhibitor 1 of the cosmetics of Examples 3 to 5 was replaced with water were used for 2 months. The degree of improvement of sexual spots was judged on the basis of ++: almost disappeared, +: obviously decreased, ±: slightly decreased,-: unchanged. The results are shown in Table 1. Thus, it can be seen that the cosmetic containing the P-related gene expression inhibitor of the present invention is excellent in the action of improving senile stains because it suppresses the expression of the P-related gene.
[0016]
[Table 1]
[0017]
【The invention's effect】
ADVANTAGE OF THE INVENTION According to this invention, the mechanism of the melanin production abnormality which was difficult to overcome by conventional techniques, such as senile stains, was clarified, and a suitable means for the prevention and improvement of such dyschromia can be provided.
[Brief description of the drawings]
FIG. 1 is a diagram showing a Northern blot of P-related gene expression inhibitor 1 of the present invention.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP08937698A JP3650697B2 (en) | 1998-03-18 | 1998-03-18 | P-related gene expression inhibitor and cosmetics containing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP08937698A JP3650697B2 (en) | 1998-03-18 | 1998-03-18 | P-related gene expression inhibitor and cosmetics containing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH11269086A JPH11269086A (en) | 1999-10-05 |
| JP3650697B2 true JP3650697B2 (en) | 2005-05-25 |
Family
ID=13968979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP08937698A Expired - Fee Related JP3650697B2 (en) | 1998-03-18 | 1998-03-18 | P-related gene expression inhibitor and cosmetics containing the same |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3650697B2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4565689B2 (en) * | 2000-02-09 | 2010-10-20 | ポーラ化成工業株式会社 | External composition for skin to suppress α-MSH |
| JP2003306418A (en) * | 2003-05-26 | 2003-10-28 | Pola Chem Ind Inc | Sunscreening cosmetic |
| JP4574959B2 (en) * | 2003-06-02 | 2010-11-04 | ポーラ化成工業株式会社 | External skin preparation for suppressing α-MSH |
| JP2009067804A (en) * | 2008-10-30 | 2009-04-02 | Pola Chem Ind Inc | SKIN EXTERNAL PREPARATION FOR WHITENING RELATING TO alpha-MSH |
-
1998
- 1998-03-18 JP JP08937698A patent/JP3650697B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH11269086A (en) | 1999-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3171637B2 (en) | Anti-aging cosmetics | |
| CN110944720A (en) | New cosmetic uses of rambutan extract | |
| CN115137677B (en) | Aqueous alcohol extract of camellia sinensis and cosmetic composition containing the same | |
| JPH07304648A (en) | Skin-beautifying cosmetic | |
| JP2001114634A (en) | Catalase protecting agent and antiager cosmetic including the same | |
| JP3650697B2 (en) | P-related gene expression inhibitor and cosmetics containing the same | |
| KR102782764B1 (en) | Cosmetic composition for skin improvement, wrinkle relief, skin soothing and skin elasticity improvement containing exosome as an effective ingredient | |
| JP4445048B2 (en) | P-related gene expression inhibitor and cosmetics containing the same | |
| JP2010070496A (en) | Agent for promoting production of hair and/or hair follicle reinforcing factor | |
| JP3889894B2 (en) | Antiallergic agents, whitening agents and skin cosmetics | |
| JPH11269024A (en) | P-related gene expression inhibitor and cosmetic containing the same | |
| JP3231908B2 (en) | Whitening cosmetics | |
| JPH11269083A5 (en) | ||
| JP2008280249A (en) | Whitening cosmetics | |
| JP2000143491A (en) | Cosmetic for caring aging | |
| JP2003012539A (en) | Cell ageing retarder | |
| JPH11269084A5 (en) | ||
| JPH11269083A (en) | P-related gene expression inhibitor and cosmetic containing the same | |
| KR101614764B1 (en) | Cosmetic composition for improving skin containing hippocampus extract and method for preparing hippocampus extract | |
| JP2009197035A (en) | External preparation for skin | |
| JPH08175954A (en) | Skin cosmetics | |
| JPH11269081A (en) | P-related gene expression inhibitor and cosmetic containing the same | |
| JPH11269085A (en) | P-related gene expression inhibitor and cosmetic containing the same | |
| JPH11269080A (en) | P-related gene expression inhibitor and cosmetic containing the same | |
| JP2778855B2 (en) | Cosmetics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040928 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041125 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050215 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050221 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |